Literature DB >> 1313740

Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.

M Treskes1, E Boven, U Holwerda, H M Pinedo, W J van der Vijgh.   

Abstract

2-(3-Aminopropylamino)ethylphosphorothioic acid (WR2721; ethiofos) was shown to selectively protect nontumor tissues from cis-diamminedichloroplatinum(II) (cisplatin)-induced toxicity, when administered 30 min prior to the platinum drug. Selectivity of protection by WR2721 is probably due to the preferential formation and uptake of the thiol metabolite 2-(3-aminopropylamino)ethanethiol (WR1065), which can inactivate toxic platinum-species inside the cell. We investigated the protective potential of WR2721, when administered at different time points relative to cisplatin. BALB/c mice treated with WR2721 (200 mg/kg i.p.) either 30 min or 5 min prior to cisplatin (i.p.) allowed a 2.2-fold increase in cisplatin dose to 19 mg/kg before the occurrence of nephrotoxicity as expressed by an increase in plasma urea. A small part of the protection could be ascribed to the mannitol (200 mg/kg), present in the formulated WR2721. WR2721 (200 mg/kg) 30 min after 14.5-16-mg/kg cisplatin did not offer any protection against the rise in plasma urea. WR2721 (200 mg/kg) 5 min before 19-mg/kg cisplatin did not cause liver toxicity (increase in serum glutamic pyruvic transaminase or serum glutamic oxaloacetic transaminase). Furthermore, WR2721 (200 mg/kg) 5 min prior to cisplatin did not reduce antitumor activity in nude mice bearing well-established human ovarian cancer xenografts. Under protection of WR2721, the dose of cisplatin could be increased by a factor of 1.6 to 8 mg/kg (administered twice weekly), resulting in an increased antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313740

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 2.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

3.  Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.

Authors:  P Bergström; A Johnsson; T Bergenheim; R Henriksson
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

Review 4.  A risk-benefit assessment of amifostine in cytoprotection.

Authors:  M Mabro; S Faivre; E Raymond
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 5.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth.

Authors:  Bikul Das; Roula Antoon; Rika Tsuchida; Shamim Lotfi; Olena Morozova; Walid Farhat; David Malkin; Gideon Koren; Herman Yeger; Sylvain Baruchel
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

7.  Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.

Authors:  J A van Laar; C L van der Wilt; M Treskes; W J van der Vijgh; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Effect of amifostine (Ethyol) on the development of extraembryonic blood vessels in chick embryos.

Authors:  J Höper; A Hanjalic; R Sauer; L Plasswilm
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

Review 9.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.

Authors:  M Treskes; U Holwerda; L G Nijtmans; H M Pinedo; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.